Haleon executives acquire shares under company reward plan

Haleon PLC ( (GB:HLN) ) just unveiled an update.

Haleon plc has disclosed share transactions by senior executives Adrian Morris, General Counsel, and Jonathan Workman, President Europe, under the company’s Share Reward Plan. Both executives acquired partnership shares and received matching shares in Haleon ordinary stock on 10 February 2026 at a market price of £3.956 per share, with trades executed on the London Stock Exchange.

The reported dealings, though small in volume, underscore ongoing alignment of key management’s interests with shareholders through equity-based incentives. The notification fulfills UK Market Abuse Regulation requirements on transparency of dealings by persons discharging managerial responsibilities, providing investors with visibility into insider participation in Haleon’s share schemes.

The most recent analyst rating on (GB:HLN) stock is a Buy with a £4.55 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on GB:HLN Stock

According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.

Haleon PLC’s overall stock score reflects strong financial performance and positive corporate events, which are the most significant factors. Technical analysis and valuation present a more mixed outlook, with some short-term challenges. The earnings call highlights regional strengths but also points to challenges in North America. Overall, the company is well-positioned for future growth, but careful management of liabilities and strategic initiatives will be crucial.

To see Spark’s full report on GB:HLN stock, click here.

More about Haleon PLC

Haleon plc (LSE/NYSE: HLN) is a global consumer health company focused on delivering everyday health products. Its portfolio spans oral health, vitamins, minerals and supplements, pain relief, respiratory and digestive health, and therapeutic skin care, led by long-standing brands such as Advil, Centrum, Panadol, Sensodyne, Theraflu and Voltaren.

Average Trading Volume: 16,334,344

Technical Sentiment Signal: Buy

Current Market Cap: £34.95B

Learn more about HLN stock on TipRanks’ Stock Analysis page.